• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

化脓性链球菌的 IgG 降解酶可导致难治性抗肾小球基底膜病患者体内的抗肾小球基底膜抗体迅速清除。

The IgG-degrading enzyme of Streptococcus pyogenes causes rapid clearance of anti-glomerular basement membrane antibodies in patients with refractory anti-glomerular basement membrane disease.

机构信息

Department of Medical Sciences, Uppsala University, Uppsala, Sweden.

Department of Pathology and Genetics, Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

出版信息

Kidney Int. 2019 Nov;96(5):1234-1238. doi: 10.1016/j.kint.2019.06.019. Epub 2019 Aug 1.

DOI:10.1016/j.kint.2019.06.019
PMID:31563334
Abstract

In anti-glomerular basement membrane (anti-GBM) disease, IgG class autoantibodies induce rapidly progressive glomerulonephritis. Regrettably, many patients are diagnosed at a late stage when even intensive conventional treatment fails to restore renal function The endopeptidase IdeS (Immunoglobulin G degrading enzyme of Streptococcus pyogenes) (imliflidase) rapidly cleaves all human IgG subclasses into F(ab') and Fc fragments. We received permission to treat three patients with refractory anti-GBM nephritis without pulmonary involvement on a compassionate basis. All patients were dialysis-dependent for days or weeks when treated, and all had high levels of circulating anti-GBM despite plasma exchange. A single dose of IdeS led to complete clearance of circulating anti-GBM antibodies in all three patients. After about a week, all rebounded but the rebounds were easily managed by plasma exchange in two of three cases. Renal histology demonstrated severe crescentic glomerulonephritis with acute but mainly chronic changes. Staining for the Fc fragment was negative in all while Fab was positive in two patients. Unfortunately, none of the patients regained independent renal function. Thus, treatment with IdeS led to rapid clearance of circulating and kidney bound anti-GBM antibodies. The clinical utility, dosing and usage to preserve renal function remain to be determined.

摘要

在抗肾小球基底膜(anti-GBM)病中,IgG 类自身抗体诱导进行性肾小球肾炎。遗憾的是,许多患者在晚期才被诊断出来,即使进行强化常规治疗也无法恢复肾功能。内切酶 IdeS(化脓性链球菌 IgG 降解酶)(imliflidase)可迅速将所有人类 IgG 亚类切割成 F(ab')和 Fc 片段。我们获得了许可,以同情的方式治疗三名无肺部受累的难治性抗 GBM 肾炎患者。所有患者在接受治疗时均已接受数天或数周的透析,尽管进行了血浆置换,但所有患者的循环抗 GBM 水平仍很高。单次 IdeS 治疗可使所有三名患者的循环抗 GBM 抗体完全清除。大约一周后,所有抗体均反弹,但在两例中,通过血浆置换很容易控制反弹。肾组织学显示严重的新月体肾小球肾炎,伴有急性但主要是慢性改变。所有患者的 Fc 片段染色均为阴性,而 Fab 染色在两名患者中为阳性。不幸的是,没有患者恢复独立的肾功能。因此,IdeS 治疗可迅速清除循环和肾脏结合的抗 GBM 抗体。其临床效用、剂量和保留肾功能的使用方法仍有待确定。

相似文献

1
The IgG-degrading enzyme of Streptococcus pyogenes causes rapid clearance of anti-glomerular basement membrane antibodies in patients with refractory anti-glomerular basement membrane disease.化脓性链球菌的 IgG 降解酶可导致难治性抗肾小球基底膜病患者体内的抗肾小球基底膜抗体迅速清除。
Kidney Int. 2019 Nov;96(5):1234-1238. doi: 10.1016/j.kint.2019.06.019. Epub 2019 Aug 1.
2
Successful treatment of experimental glomerulonephritis with IdeS and EndoS, IgG-degrading streptococcal enzymes.用 IdeS 和 EndoS(两种能降解 IgG 的链球菌酶)成功治疗实验性肾小球肾炎。
Nephrol Dial Transplant. 2010 Aug;25(8):2479-86. doi: 10.1093/ndt/gfq115. Epub 2010 Mar 10.
3
A case of aggressive atypical anti-GBM disease complicated by CMV pneumonitis.抗肾小球基底膜病合并巨细胞病毒肺炎一例。
BMC Nephrol. 2019 Jan 31;20(1):29. doi: 10.1186/s12882-019-1227-z.
4
Using imlifidase to elucidate the characteristics and importance of anti-GBM antibodies produced after start of treatment.使用 imlifidase 阐明治疗开始后产生的抗 GBM 抗体的特征和重要性。
Nephrol Dial Transplant. 2023 Dec 20;39(1):45-54. doi: 10.1093/ndt/gfad132.
5
Anti-glomerular basement membrane disease (Goodpasture disease): From pathogenesis to plasma exchange to IdeS.抗肾小球基底膜病(Goodpasture 病):从发病机制到血浆置换再到 IdeS。
Ther Apher Dial. 2022 Feb;26(1):24-31. doi: 10.1111/1744-9987.13718. Epub 2021 Aug 10.
6
IdeS in anti-glomerular basement membrane disease: Is this the new deal?抗肾小球基底膜病中的 IdeS:这是新疗法吗?
Kidney Int. 2019 Nov;96(5):1068-1070. doi: 10.1016/j.kint.2019.08.017.
7
The evolution of crescentic nephritis and alveolar haemorrhage following induction of autoimmunity to glomerular basement membrane in an experimental model of Goodpasture's disease.在古德帕斯彻氏病实验模型中,诱导针对肾小球基底膜的自身免疫后新月体性肾炎和肺泡出血的演变。
J Pathol. 2003 May;200(1):118-29. doi: 10.1002/path.1336.
8
Endopeptidase Cleavage of Anti-Glomerular Basement Membrane Antibodies in Severe Kidney Disease: An Open-Label Phase 2a Study.严重肾脏疾病中抗肾小球基底膜抗体的内肽酶切割:一项开放标签 2a 期研究。
J Am Soc Nephrol. 2022 Apr;33(4):829-838. doi: 10.1681/ASN.2021111460. Epub 2022 Mar 8.
9
Goodpasture's disease: a report of ten cases and a review of the literature.Goodpasture 综合征:10 例报告及文献复习。
Autoimmun Rev. 2013 Sep;12(11):1101-8. doi: 10.1016/j.autrev.2013.06.014. Epub 2013 Jun 24.
10
Rapidly progressive glomerulonephritis due to anti-glomerular basement membrane disease accompanied by IgA nephropathy: An unusual association.抗肾小球基底膜病伴IgA肾病所致快速进展性肾小球肾炎:一种不寻常的关联。
Saudi J Kidney Dis Transpl. 2017 Nov-Dec;28(6):1404-1407. doi: 10.4103/1319-2442.220866.

引用本文的文献

1
Molecular basis of Fab-dependent IgA antibody recognition by gut-bacterial metallopeptidases.肠道细菌金属肽酶对Fab依赖性IgA抗体识别的分子基础
EMBO J. 2025 Jul 31. doi: 10.1038/s44318-025-00518-w.
2
Management dilemma of anti-GBM disease and p-ANCA-associated vasculitis with necrotizing skin lesions in a pediatric patient.一名儿科患者抗肾小球基底膜病合并伴坏死性皮肤病变的抗中性粒细胞胞浆抗体相关性血管炎的管理困境
Pediatr Nephrol. 2025 Mar 3. doi: 10.1007/s00467-025-06721-5.
3
Half-Life Extension of the IgG-Degrading Enzyme (IdeS) Using Fc-Fusion Technology.
利用Fc融合技术延长IgG降解酶(IdeS)的半衰期
Eur J Immunol. 2025 Feb;55(2):e202451264. doi: 10.1002/eji.202451264. Epub 2024 Dec 20.
4
Imlifidase in kidney transplantation.依姆利菲酶在肾移植中的应用
Clin Kidney J. 2024 Feb 9;17(3):sfae033. doi: 10.1093/ckj/sfae033. eCollection 2024 Mar.
5
The Immunobiological Agents for Treatment of Antiglomerular Basement Membrane Disease.用于治疗抗肾小球基底膜病的免疫生物制剂。
Medicina (Kaunas). 2023 Nov 16;59(11):2014. doi: 10.3390/medicina59112014.
6
Using imlifidase to elucidate the characteristics and importance of anti-GBM antibodies produced after start of treatment.使用 imlifidase 阐明治疗开始后产生的抗 GBM 抗体的特征和重要性。
Nephrol Dial Transplant. 2023 Dec 20;39(1):45-54. doi: 10.1093/ndt/gfad132.
7
Adeno-associated virus-vectored delivery of HIV biologics: the promise of a "single-shot" functional cure for HIV infection.腺相关病毒载体递送HIV生物制剂:实现HIV感染“单次注射”功能性治愈的前景。
J Virus Erad. 2023 Feb 17;9(1):100316. doi: 10.1016/j.jve.2023.100316. eCollection 2023 Mar.
8
New Insights into the Pathogenesis and Treatment Strategies in IgA Nephropathy.IgA肾病发病机制与治疗策略的新见解
Glomerular Dis. 2021 Oct 1;2(1):15-29. doi: 10.1159/000519973. eCollection 2022 Jan.
9
The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A mice.IgG 降解酶 Imlifidase 可恢复抑制剂阳性血友病 A 小鼠中 FVIII 的治疗活性。
Haematologica. 2023 May 1;108(5):1322-1334. doi: 10.3324/haematol.2022.281895.
10
Epidemiology, Impact, and Management Strategies of Anti-Glomerular Basement Membrane Disease.抗肾小球基底膜病的流行病学、影响及管理策略
Int J Nephrol Renovasc Dis. 2022 Apr 7;15:129-138. doi: 10.2147/IJNRD.S326427. eCollection 2022.